Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Imaging and biopsy in selecting patients for breast surgery omission trials

Han-Byoel Lee, MD, PhD, Seoul National University Hospital, Seoul, South Korea, comments on the critical role of imaging evaluation and tissue confirmation in determining candidacy for surgery omission trials in breast cancer. Imaging findings alone following neoadjuvant systemic therapy may be insufficient, where the JCOG1806 (jRCTs031190129) trial highlighted the importance of standardizing biopsy protocols. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

The key to the success of omission of surgery trials is the prediction or the evaluation of residual tumor on imaging. That’s the initial evaluation. And plus the imaging, we will probably need biopsych confirmation, tissue confirmation through vacuum assisted biopsy. We will have to look into the results from the JCOC 1806 trial where a lot of those patients did not even have a biopsey. And a lot the patients that did receive biopisy, they didn’t pre-specify the number of cores, the size of the needle, or anything like that...

The key to the success of omission of surgery trials is the prediction or the evaluation of residual tumor on imaging. That’s the initial evaluation. And plus the imaging, we will probably need biopsych confirmation, tissue confirmation through vacuum assisted biopsy. We will have to look into the results from the JCOC 1806 trial where a lot of those patients did not even have a biopsey. And a lot the patients that did receive biopisy, they didn’t pre-specify the number of cores, the size of the needle, or anything like that. so we will have to see the IMPACT of not specifying the modality of the biopsy and not doing the biopsies at all in those patients, which were pretty early in the stage. But I truly believe that the imaging findings after neurodegenerative therapy may not be enough. We have a lot of studies that show that. So to make it safe, imaging information plus a biopsy of the tumor bed where the tumor used to be before neurodegenerative systemic therapy will add the accuracy about the potential, not potential, about the pathologic CR complete response in the patient and thus provide the evidence for omitting surgery in those patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.